0001213900-26-055059
SEC filingNet loss widened to $19.1M in Q1 FY2026, driven by higher operating expenses, though EPS improved to -$0.22 on a significantly larger share count.
Relmada is advancing its pipeline, including a planned pivotal Phase 3 study in intermediate-risk non-muscle invasive bladder cancer (NMIBC) in the adjuvant setting. The study design reflects FDA guidance on population, endpoint, and methodology. Additionally, the company has filed provisional patent applications with expected term through April 2047, strengthening its intellectual property position. Management continues to evaluate strategic opportunities to maximize shareholder value while maintaining financial discipline.